Document:

EX-10.6

 Exhibit 10.6 

SILVERBACK THERAPEUTICS, INC. 

July 23, 2016 
 Valerie Odegard 

Re: This offer supersedes offer dated July 19, 2016 

Dear Valerie, 
 This will confirm the terms
under which Silverback Therapeutics, Inc., a Delaware corporation (the “Company”) has made you an offer of employment: 

1. Position and Duties. You will serve as Sr. Vice President, Translational Sciences such duties as are ordinary,
customary and necessary in such role (subject to the limitations set forth in the next paragraph). You will report Peter Thompson although such reporting is subjectto change from time to time. Your start date with the Company shall be
October 24, 2016. You shall devote your full business time, skill and attention to the performance of your duties on behalfof the Company. You will devote your efforts to the interests of the Company as set forth in the preceding sentence and
will not engage in other employment or in any activities detrimental to the interests of the Company without the prior written consent of the Company. 

2. Proof of Right to Work; Assignment Agreement. On your first day of work you will be required to prove your eligibility
for employment under the Immigration and Reform Control Act of 1986, as well as to sign and comply with the Company’s standard proprietary information and invention assignment (“PIIA”) which requires, among
other provisions, the assignment of patent rights to any invention made during your employment at the Company and non-disclosure of proprietary information. 

3. Compensation and Benefits. 

a) Salary. The Company agrees to pay you an annualized salary of $260,000.00, payable as earned in accordance with the
Company’s customary payroll practices (Bi-weekly). Your salary shall be reviewed by the Board of Directors of the Company (the “Board”) for possible increases
annually. 
 b) Stock Options. Subject to approval of the Board, you will receive an option to purchase 225,212 shares
of the Company’s common stock (the “Option”) pursuant to the Company’s 2016 Equity Incentive Plan. The per share price of the Option will be equal to the per share fair market value of the common stock
on the date of grant, as determined by the Board. The Option will be contingent upon you executing the Company’s standard stock option agreement. So long as you continue in service with the Company, the Option will vest and become exercisable
as follows: 

  
 1 

 (i) with respect to 57,204 shares of Common Stock, 25% of such amount (14,301 shares) shall
become vested on the one year anniversary of your start date with the Company, with the remaining 42,903 shares becoming vested in equal monthly installments over 36 months following such one year anniversary; 

(ii) with respect 84,004 shares of Common Stock, 25% of such amount (21,001 shares) shall become vested, if at all, on the one year
anniversary of the Company’s issuance of its Series A Preferred Stock in a Second Tranche Closing (as defined in the Company’s Series A Preferred Stock Purchase Agreement), with the remaining 63,003 shares becoming vested in equal monthly
installments over 36 months following such one year anniversary; and 
 (iii) with respect to 84,004 shares of Common Stock, 25% of such
amount (21,001 shares) shall become vested, if at all, on the one year anniversary of the Company’s issuance of its Series A Preferred Stock in a Third Tranche Closing (as defined in the Company’s Series A Preferred Stock Purchase
Agreement), with the remaining 63,003 shares becoming vested in equal monthly installments over 36 months following such one year anniversary. 

For clarity, in the event that the Second Tranche Closing does not occur, no sharesof Common Stock set forth in subsection (ii) above
shall vest, and in the event that the Third Tranche Closing does not occur, no shares of Common Stock set forth in subsection (iii) shall vest. 

c) Bonus Potential. You will be eligible to receive a cash bonus up to 25%of your annual base salary subject to
performance milestones and other terms and conditions approved by the Board. The 2016 bonus will be prorated to reflected the equivalent of a six-month period. The approved 2016 bonus payment will be paid
during the first quarter of 2017. 
 d) Benefits. You will be eligible to participate in regular health insurance,
vacation, and other employee benefit plans established by the Company for its employees from time to time on substantially the same terms as are made available to employees of the Company generally. 

e) Expenses. The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with
the Company’s business, in accordance with any applicable policy established by the Board from time to time. 
 4. At-Will Employment. You will be an at will employee of the Company, which means that the employment relationship can be terminated by either you or the Company for any reason or no reason, at any time, with
or without prior notice and with or without cause. Any statements or representations to the contrary should be regarded by you as ineffective. Any modification or change in the at-will employment status may
only occur by way of a written employment agreement signed by you and an authorized member of the Board. 
 5. Other
Agreements. By signing this offer letter, you represent and warrant to the Company that either (a) you are not bound by any other agreement or agreements (i.e., a non-solicitation or non-compete agreement with a former employer) which would inhibit or limit in any way your ability to perform the duties required by this position or to contact, solicit, or hire

  
 2 

 
any other individual or entity to work for or contract with the Company or (b) you have provided copies of any such agreements to the Company prior to signing this offer letter. 

6. Miscellaneous. This offer letter constitutes the entire agreement between you and the Company regarding the terms and
conditions of your employment, and they supersede all prior negotiations, representations, or agreements between you and the Company. The provisions of this agreement may only be modified by a document signed by you and the Company. This offer
letter will be governed by the laws of the State of Washington. 
 7. Expiration. This offer shall expire on
July 29,2016. Please verbally reply to this offer by this date by calling me. It is understood that the written acceptance of this offer letter will coincide with your resignation from your current position anticipated to be within 30 days to
your start date above. At that time please sign the offer letter and return it with a signed copy of the Company’s standard PIIA, a copy of which is attached for your review as Exhibit A. 

I am delighted that you will be joining our team and I am looking forward to working with you. If you have any questions, please give me a
call. 
  

			
	 Very truly yours,
  

Silverback Therapeutics, Inc.

		
	By:	 	/s/ Peter Thompson
		 	 Peter Thompson
 President and Chief Executive
Officer

 AGREED TO AND ACCEPTED BY: 

/s/ Valerie
Odegard                             

Valerie Odegard 
 Date: 10/22/16 

Enclosure: Proprietary Information and Invention Agreement 

  
 3EX-10.7

 Exhibit 10.7 
  

			
	 

	  	 Silverback Therapeutics, Inc.
 500 Fairview
Avenue North Suite 600
 Seattle, WA 98109

 December 22, 2018 
 Naomi
Hunder, MD 
 Via email 
 Dear Naomi, 

This will confirm the terms under which Silverback Therapeutics, Inc., a Delaware corporation (the “Company”) has made
you an offer of full-time employment: 
 1. Position and Duties. You will serve as Sr. Vice President, Clinical Research
and Development and shall perform such duties as are ordinary, customary and necessary in such role (subject to the limitations set forth in the next paragraph). You will report to me. Your start date with the Company shall be January 14, 2019.
You shall devote your full business time, skill and attention to the performance of your duties on behalf of the Company. You will devote your efforts to the interests of the Company as set forth in the preceding sentence and will not engage in
other employment or in any activities detrimental to the interests of the Company without the prior written consent of the Company. 

2. Proof of Right to Work; Assignment Agreement. On your first day of work you will be required to prove your eligibility
for employment under the Immigration and Reform Control Act of 1986, as well as to sign and comply with the Company’s standard proprietary information and invention assignment (“PIIA”) which requires, among other
provisions, the assignment of patent rights to any invention made during your employment at the Company and non-disclosure of proprietary information. 

3. Compensation and Benefits. 

a) Salary. The Company agrees to pay you annualized salary of $340,000, payable as earned in accordance with the
Company’s customary payroll practices. Your salary shall be reviewed by the Board of Directors of the Company (the “Board”) for possible increases annually. 

b) Stock Options. Subject to approval of the Board, you will receive an option to purchase 164,336 shares of the
Company’s common stock (the “Option”) pursuant to the Company’s 2016 Equity Incentive Plan. The per share price of the Option will be equal to the per share fair market value of the common stock on the date of
grant, as determined by the Board. The Option will be contingent upon you executing the Company’s standard stock option agreement. The vesting schedule for this option will be detailed in the stock option agreement. 

c) Bonus Potential. You will be eligible to earn a cash bonus up to 30% of your annual base salary subject to performance
milestones and other terms and conditions approved by the Board. 
 d) Benefits. You will be eligible to participate in
regular health insurance, vacation, and other employee benefit plans established by the Company for its employees from time to time on substantially the same terms as are made available to employees of the Company generally. 

4. At-Will Employment. You will be an at will employee of the Company, which
means 

 
that the employment relationship can be terminated by either you or the Company for any reason or no reason, at any time, with or without prior notice and with or without cause. Any statements or
representations to the contrary should be regarded by you as ineffective. Any modification or change in the at-will employment status may only occur by way of a written employment agreement signed by you
and an authorized member of the Board. 
 5. Other Agreements. By signing this offer letter, you represent and warrant
to the Company that either (a) you are not bound by any other agreement or agreements (i.e., a non-solicitation or non-compete agreement with a former employer)
which would inhibit or limit in any way your ability to perform the duties required by this position or to contact, solicit, or hire any other individual or entity to work for or contract with the Company or (b) you have provided copies of any
such agreements to the Company prior to signing this offer letter. 
 6. Miscellaneous. This offer letter constitutes
the entire agreement between you and the Company regarding the terms and conditions of your employment, and they supersede all prior negotiations, representations, or agreements between you and the Company. The provisions of this agreement may only
be modified by a document signed by you and the Company. This offer letter will be governed by the laws of the State of Washington. 

7. Expiration. This offer shall expire on December 28, 2018, and is subject to you signing the Company’s
standard PIIA, a copy of which is attached for your review as Exhibit A. 
 Please indicate your acceptance to the foregoing terms by
signing this letter where indicated below and returning it to Lindsay Blackner. 
 I am delighted that you will be joining our team and I am
looking forward to working with you. 
  

			
	 Very truly yours,
 Silverback
Therapeutics, Inc.

		
	By:	 	/s/ Peter A. Thompson
		 	 Peter A. Thompson, MD, FACP

President & CEO

 AGREED TO AND ACCEPTED BY: 

/s/ Naomi
Hunder                                 

Naomi Hunder 
 Date: December 23, 2018 

Enclosure: Proprietary Information and Invention Agreement 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]